Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells

Lei Wang, Jianfang Ning, Hiroaki Wakimoto, Shulin Wu, Chin lee Wu, Melissa R. Humphrey, Samuel D. Rabkin, Robert L. Martuza

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Novel therapies to override chemo-radiation resistance in prostate cancer (PCa) are needed. Prostate cancer sphere-forming cells (PCSCs) (also termed prostate cancer stem-like cells) likely participate in tumor progression and recurrence, and they are important therapeutic targets. We established PCSC-enriched spheres by culturing human (DU145) and murine (TRAMP-C2) PCa cells in growth factor-defined serum-free medium, and we characterized stem-like properties of clonogenicity and tumorigenicity. The efficacy of two different oncolytic herpes simplex viruses (oHSVs) (G47Δ and MG18L) in PCSCs was tested alone and in combination with radiation; chemotherapy; and inhibitors of phosphoinositide 3-kinase (PI3K), Wnt, and NOTCH in vitro; and, G47Δ was tested with the PI3K inhibitor BKM120 in a PCSC-derived tumor model in vivo. PCSCs were more tumorigenic than serum-cultured parental cells. Human and murine PCSCs were sensitive to oHSV and BKM120 killing in vitro, while the combination was synergistic. oHSV combined with radiation, docetaxel, Wnt, or NOTCH inhibitors was not. In athymic mice bearing DU145 PCSC-derived tumors, the combination of intra-tumoral G47Δ and systemic BKM120 induced complete regression of tumors in 2 of 7 animals, and it exhibited superior anti-tumor activity compared to either monotherapy alone, with no detectable toxicity. oHSV synergizes with BKM120 in killing PCSCs in vitro, and the combination markedly inhibits tumor growth, even inducing regression in vivo.

Original languageEnglish (US)
Pages (from-to)58-66
Number of pages9
JournalMolecular Therapy - Oncolytics
Volume13
DOIs
StatePublished - Jun 28 2019

Bibliographical note

Funding Information:
These studies were supported in part by a grant from NIH to R.L.M. (R01CA102139).

Funding Information:
These studies were supported in part by a grant from NIH to R.L.M. ( R01CA102139 ).

Publisher Copyright:
© 2019 The Author(s)

Keywords

  • BKM120
  • DU145
  • G47Δ
  • MG18L
  • PI3K inhibitor
  • TrampC2
  • herpes virus
  • oncolytic virus
  • prostate cancer
  • prostate cancer stem-like cells

Fingerprint

Dive into the research topics of 'Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells'. Together they form a unique fingerprint.

Cite this